Importance of apolipoprotein A-I in multiple sclerosis
Jean-Martin Charcot has first described multiple sclerosis (MS) as a disease of the central nervous system (CNS) over a century ago. MS remains incurable today, and treatment options are limited to disease modifying drugs. Over the years, significant advances in understanding disease pathology have...
Main Authors: | Lidia A Gardner, Michael C Levin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00278/full |
Similar Items
-
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01) -
Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
by: Kensuke Senzaki, et al.
Published: (2021-06-01) -
Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
by: Ryoko Fukai, et al.
Published: (2019-07-01) -
Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency
by: Gulin Sunter, et al.
Published: (2018-04-01) -
The Apolipoprotein M–Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis
by: Bas W. C. Arkensteijn, et al.
Published: (2013-02-01)